<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940419-1-00012</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Written comments by May 4, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4702 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Part 343</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 77N&hyph;094U]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=91 g=1 f=1 -->  <RINDOCK>RIN 0905&hyph;AA06</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Proposed Amendment to Tentative Final Monograph; Reopening of Comment Period <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice of proposed rulemaking; reopening of comment period. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is reopening to May 4, 1994, the comment period on the notice of proposed rulemaking pertaining to combinations of over-the-counter (OTC) internal analgesic and antacid ingredients, specifically sodium bicarbonate used as an antacid active ingredient (February 2, 1994, 59 FR 5068). FDA is taking this action in response to a request to extend the comment period for an additional 30 days to allow more time to comment on this proposal. The comment period for these issues closed on April 4, 1994. This proposal is part of the ongoing review of OTC drug products conducted by FDA. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Written comments by May 4, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Written comments to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> William E. Gilbertson, Center for Drug Evaluation and Research (HFD&hyph;810), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;594&hyph;5000. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  of February 2, 1994 (59 FR 5068), FDA issued a notice of proposed rulemaking to amend the tentative final monograph for OTC internal analgesic, antipyretic, and antirheumatic drug products (hereinafter referred to as the February 1994, proposal). This proposal affected combinations of internal analgesic and antacid ingredients, specifically sodium bicarbonate used as an antacid active ingredient. As proposed, combination drug products intended to be dissolved in liquid prior to administration, such as powders and effervescent granules or tablets, would not be allowed to make a claim for ``relief of overindulgence in food and drink'' or a claim for ``relief of hangover.'' FDA issued the February 1994, proposal after receiving reports of gastric (stomach) rupture following ingestion of sodium bicarbonate to relieve gastrointestinal distress. Interested persons were given until April 4, 1994, to submit comments on the proposal. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> On March 28, 1994, the Nonprescription Drug Manufacturers Association (NDMA), a trade association representing the manufacturers and distributors of OTC medicines, requested that the comment period be extended for at least 30 days. NDMA stated that the extension is necessary to provide sufficient time to develop comprehensive comments to submit to the agency. NDMA explained that most companies that distribute OTC drug products containing sodium bicarbonate as an active ingredient were not anticipating changes in the internal analgesic, antipyretic, and antirheumatic tentative final monograph and the February 1994, proposal provided the first opportunity for many affected parties to become aware of the agency's concerns and intentions for amending the tentative final monograph. NDMA stated that interested parties have had insufficient time to acquire the reference materials cited by FDA, to retrieve relevant product experience reports, and to research thoroughly the issues raised in FDA's February 1994, proposal. NDMA also mentioned that the time period for the comments includes several days on which many company employees will not be working because of religious holidays. <!-- PJG 0012 frnewline --> FDA has carefully considered the request and believes that this additional time for comment is in the public interest. Accordingly, the comment period is reopened to May 4, 1994. <!-- PJG 0012 frnewline --> Interested persons may, on or before May 4, 1994, submit to the Dockets Management Branch (address above) written comments regarding OTC internal analgesic, antipyretic, and antirheumatic drug products containing sodium bicarbonate as an antacid active ingredient. Three copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: April 13, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Michael R. Taylor, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;9354 Filed 4&hyph;18&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            